7月15日公司发布上半年业绩预告，预计实现净利润-4500.00万元至-3800.00万元，同比变动区间 为-171.56%~-160.42%。（数据宝） （文章来源：证券时报网） 证券时报·数据宝统计显示，联环药业所属的医药生物行业，目前整体涨幅为1.44%，行业内，目前股价 上涨的有438只，涨停的有福瑞股份、济民健康等3只。股价下跌的有48只，跌幅居前的有南模生物、皓 宸医疗、广誉远等，跌幅分别为4.23%、4.01%、3.62%。 公司发布的一季报数据显示，一季度公司共实现营业收入6.28亿元，同比增长18.78%，实现净利润 2305.96万元，同比下降29.15%，基本每股收益为0.0800元，加权平均净资产收益率1.64%。 注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 联环药业股价再创历史新高，该股近期呈不断突破新高之势，近一个月累计有10个交易日股价刷新历史 纪录。截至09:40，该股目前上涨2.66%，股价报28.52元，成交1131.11万股，成交金额3.15亿元，换手 率3.96%，该股最新A股总市值达81.41亿元，该股A股流通市值81.41亿元。 ...

Group 1 - The stock price of Lianhuan Pharmaceutical is reported at 25.05 yuan, down 1.02 yuan from the previous trading day [1] - The stock opened at 25.38 yuan, reached a high of 26.74 yuan, and a low of 25.01 yuan, with a total trading volume of 1.199 billion yuan [1] - Lianhuan Pharmaceutical operates in the chemical pharmaceutical sector, with business activities including innovative drug research and development [1] Group 2 - The company has a total market capitalization of 7.151 billion yuan, with circulating market value equal to total market value [1] - On August 14, the stock experienced rapid fluctuations, with a rebound of over 2% within 5 minutes at 9:37 AM, followed by a decline of over 2% within 5 minutes at 9:42 AM [1] - The net outflow of main funds on that day was 161 million yuan, accounting for 2.25% of the circulating market value, with a cumulative net outflow of 95.3544 million yuan over the past five trading days, representing 1.33% of the circulating market value [1]

证券代码：600513 证券简称：联环药业 公告编号：2025—057 江苏联环药业股份有限公司 股票交易异常波动的公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 1、江苏联环药业股份有限公司（以下简称"公司"）股票于 2025 年 8 月 8 日、8 月 11 日、8 月 12 日连续三个交易日内收盘价格涨幅偏离值累计超过 20%， 根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动。 2、经公司自查并书面征询公司控股股东和实际控制人，截至本公告披露日， 控股股东及实际控制人不存在应披露而未披露的重大信息，包括但不限于重大资 产重组、股份发行、重大交易类事项、业务重组、股份回购、破产重整、重大业 务合作、引进战略投资者等重大事项。 3、公司 2025 年半年度实现归属于上市公司股东的净利润区间预计为 -4,500.00 万元人民币至-3,800.00 万元人民币，与上年同期相比将减少 10,088.79 万元人民币到 10,788.79 万元人民币，业绩由盈转亏。 4、公司股票价格自 2025 ...

关于江苏联环药业股份有限公司股票交易 异常波动询证函的回复 我公司在本次股票异常波动期间未买卖联环药业股票。 江苏联环药业集团有限公司 江苏联环药业股份有限公司: 《江苏联环药业股份有限公司关于公司股票交易异常 波动的询证函》收悉,经自查确认,现回复如下: 我公司作为江苏联环药业股份有限公司（以下简称"联" 环药业")的控股股东,截至目前,除联环药业在指定媒体 已披露信息之外,我公司不存在影响联环药业股票价格异常 波动的重大事项;不存在应披露而未披露的重大信息,包括 但不限于重大资产重组、股份发行、上市公司收购、债务重 组、业务重组、资产剥离、资产注入、股份回购、股权激励、 引进战略投资者等重大事项。 同时,经与扬州市国有资产监督管理委员会(以下简称 "扬州市国资委")确认,截至目前,扬州市国资委作为联 环药业的实际控制人,除联环药业在指定媒体已披露信息之 外,扬州市国资委不存在影响联环药业股票价格异常波动的 重大事项;不存在应披露而未披露的重大信息,包括但不限 于重大资产重组、股份发行、上市公司收购、债务重组、业 务重组、资产剥离、资产注入、股份回购、股权激励、引进 战略投资者等重大事项。 我公司亦将严格遵 ...

Core Viewpoint - The National Market Supervision Administration of China has imposed administrative penalties on four pharmaceutical companies for engaging in a monopoly agreement, resulting in a total fine exceeding 362 million yuan [1][2]. Group 1: Companies Involved - The companies involved in the monopoly agreement are Tianjin Pharmaceutical Industry Co., Ltd. (津药药业), Zhejiang Xianju Pharmaceutical Co., Ltd. (仙琚制药), Jiangsu Lianhuan Pharmaceutical Co., Ltd. (联环药业), and Xi'an Guokang Ruijin Pharmaceutical Co., Ltd. (国康瑞金制药) [1]. - Among these, Lianhuan Pharmaceutical, Tianjin Pharmaceutical, and Xianju Pharmaceutical hold the approval for the injection of dexamethasone phosphate sodium and have undergone consistency evaluation [2]. Group 2: Penalties and Financial Impact - The total fines imposed include 500,000 yuan on the individual responsible, confiscation of illegal gains, and an 8% fine on the previous year's sales for the four companies, amounting to approximately 355 million yuan [2]. - For Lianhuan Pharmaceutical, the penalty represents 2.83% of the company's audited revenue and 72.53% of the net profit attributable to shareholders for the most recent fiscal year [2]. - The penalty will reduce the net profit attributable to shareholders for Lianhuan Pharmaceutical by approximately 61.0382 million yuan for the fiscal year 2025 [2]. Group 3: Market Impact - The companies coordinated to raise the price of dexamethasone phosphate sodium from 8,000 yuan per kilogram to 13,000 yuan between February 2022 and March 2024, significantly restricting market competition and increasing healthcare costs for consumers [1].

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. has shown a significant stock price increase and strong revenue growth, indicating a positive market response and operational performance despite a decline in net profit [1] Company Overview - Jiangsu Lianhuan Pharmaceutical is located in Yangzhou, Jiangsu Province, and is recognized as a national high-tech enterprise [1] - The company integrates research and development, production, and sales, specializing in various pharmaceutical forms including tablets, hard capsules, suppositories, and granules, with an annual production capacity of 5 billion units [1] - Its main product lines include urological, antihistamine, cardiovascular, steroid hormone, and antibiotic categories, featuring over 100 varieties, including key products like the first-class new drug Aipulete and second-class new drug Ebastine [1] - The company boasts a high-end R&D team of nearly 200 members and multiple research platforms [1] Financial Performance - For the period from January to March 2025, the company achieved operating revenue of 628 million yuan, representing a year-on-year growth of 18.78% [1] - However, the net profit attributable to shareholders was 23.06 million yuan, reflecting a year-on-year decrease of 29.15% [1] - As of March 31, the number of shareholders was 30,300, with an average of 9,416 circulating shares per person [1] Market Activity - On August 12, the company's stock price increased by 6.13%, reaching 25.44 yuan per share, with a trading volume of 926 million yuan and a turnover rate of 13.25% [1] - The total market capitalization of Jiangsu Lianhuan Pharmaceutical is 7.262 billion yuan [1]

Meeting Overview - The first temporary shareholders' meeting of Jiangsu Lianhuan Pharmaceutical Co., Ltd. was held on August 11, 2025, at the company's conference room in Yangzhou [2] - The meeting was legally convened and presided over by Chairman Qian Zhenhua, utilizing a combination of on-site and online voting methods [2][3] Resolutions Passed - The following resolutions were approved during the meeting: 1. Election of Ms. Wu Fang as an independent director [4] 2. Proposal for the company to issue technology innovation bonds [4] - All current directors and supervisors were present during the voting process [4] Legal Verification - The meeting was witnessed by Beijing Zhonglun (Chengdu) Law Firm, confirming that the convening and voting procedures complied with relevant laws and regulations [6] Committee Adjustments - Following the election of a new independent director, adjustments were made to the members of the Audit Committee and the Nomination Committee: 1. Audit Committee: Changed from Zhang Bin (convener), Chen Ying, Tu Bin to Zhang Bin (convener), Wu Fang, Tu Bin [9] 2. Nomination Committee: Changed from Hu Yiqiao (convener), Chen Ying, Qian Zhenhua to Hu Yiqiao (convener), Wu Fang, Qian Zhenhua [9]

证券代码：600513 证券简称：联环药业 公告编号：2025-055 江苏联环药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ?本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2025 年 8 月 11 日 | | 议案名称 | | | | | | 比例 | | --- | --- | --- | --- | --- | --- | --- | --- | | 序号 | | 票数 | 比例（%） | 票数 | 比例（%） | 票数 | | | | | | | | | （%） | | 《关于选举吴方女士为 (二)股东会召开的地点：扬州生物健康产业园健康一路 9 号联环药业会议室 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议经过适当的召集和通知程序，由公司董事长钱振华先生主持，采用 了现场投票与网络投票相结合的表决方式，符合《中华人民共和国公司法》、中 国证监会《 ...

（文章来源：证券日报） 证券日报网讯 8月11日晚间，联环药业发布公告称，公司2025年第一次临时股东会于2025年8月11日召 开，审议通过了《关于公司拟发行科技创新债券的议案》等。 ...

New Stock Issuance - Hongyuan Co., Ltd. (stock code: 920018) issued shares at a price of 9.17 on August 11, 2025[1] - China Shipbuilding Industry Corporation (stock code: 600150) has a cash acquisition request period from August 13 to August 15, 2025[1] - ST Kelly (stock code: 300326) has a tender offer period from July 17 to August 15, 2025[1] Rights and Announcements - China Heavy Industry (stock code: 601989) has a cash option declaration period starting August 13, 2025[1] - Fushun Special Steel (stock code: 600399) has a tender offer period from August 12 to September 10, 2025[1] - North Long Dragon (stock code: 301357) has an announcement link for further details[1] Market Volatility - Several stocks, including ST Xifa (stock code: 000752) and ST Aowei (stock code: 002231), are under observation for significant price fluctuations[1] - The report highlights abnormal fluctuations in stocks such as ST Songfa (stock code: 603268) and ST Yancheng (stock code: 603063)[2]